Tradestie Institutional Equity Comparison Engine
FITZ vs PRME โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PRME Overall Edge
PRME Captures Institutional Edge (3โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Prime Medicine, Inc. Common Stock (PRME) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, FITZ trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus PRME at N/M Forward P/E and -2584.2% operating margin (+243.9% YoY). In options structure, FITZ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PRME sits in SURGE (32nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
FITZ N/M vs PRME N/M Fwd P/E
Growth & Margin Winner
PRME
Op Margin N/A vs -2584.2% ยท YoY N/A vs +243.9%
Momentum & Technical Winner
PRME
1Y +0.5% vs +25.8% ยท 52W Pos 16% vs 47%
Options & Structure Winner
PRME
UNCLASSIFIED (N/A IV) vs SURGE (32nd %ile IV)
FITZ
US Equity
FITZ
Institutional Equity
$25.44
-2.15% 1D
Market Cap
N/A
1M Return
-1.74%
1Y Return
+0.51%
Forward P/E
N/M
Unified AI Score
57.6 / 100
HOLD
Tech 45.0
Fund 59.0
Flow 50.0
Mom 50.0
PRME
NASDAQ
Prime Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.19
-1.87% 1D
Market Cap
$949.9M
1M Return
+20.75%
1Y Return
+25.83%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 53.0
Fund 54.0
Flow 65.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
FITZ +0.51%
PRME +25.83%
Spread: +22.73 pp (PRME Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
FITZ TTM Op. Margin: N/A
PRME TTM Op. Margin: -2584.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FITZ vs PRME. Trailing 12-month operating profitability (FITZ N/A vs PRME -2584.2%) and valuation multiples (FITZ N/M vs PRME N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FITZ | PRME | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $949.9M | Larger Scale | PRME |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +243.9% | Higher Growth | PRME |
| Operating Margin (TTM) Profitability | N/A | -2584.2% | Higher Margin | PRME |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | PRME |
| Return on Equity (ROE) Capital Efficiency | N/A | -207.2% | Higher ROE | PRME |
| 52-Week Range Position Momentum | 16% ($23โ$36) | 47% ($3โ$6) | Stronger Trend | PRME |
| Beta / 30D Volatility Risk Regime | 1.00ฮฒ ยท 27% Vol | 2.45ฮฒ ยท 149% Vol | Lower Realized Risk | FITZ |
| Unified Institutional Score Composite Signal | 57.6 / 100 (HOLD) | 52.2 / 100 (HOLD) | Higher Composite | FITZ |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full FITZ vs PRME Buy Guide
FITZ
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
PRME
SURGE
13d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
32nd %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither FITZ nor PRME registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.